Axon Enterprise (NASDAQ:AXON) Price Target Raised to $700.00 at The Goldman Sachs Group

Axon Enterprise (NASDAQ:AXON) had its price target hoisted by equities researchers at The Goldman Sachs Group from $500.00 to $700.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price points to a potential upside of 9.80% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the stock. JMP Securities boosted their price objective on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $500.00 to $700.00 in a report on Tuesday, December 3rd. TD Cowen initiated coverage on Axon Enterprise in a report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price objective for the company. Northland Securities boosted their target price on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, Robert W. Baird upped their target price on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $524.85.

Axon Enterprise Stock Up 5.4 %

Shares of NASDAQ AXON opened at $637.53 on Monday. The firm’s fifty day moving average is $618.29 and its 200 day moving average is $476.64. Axon Enterprise has a 52 week low of $247.04 and a 52 week high of $698.67. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The company has a market cap of $48.61 billion, a price-to-earnings ratio of 164.74, a PEG ratio of 6.09 and a beta of 1.04.

Insider Activity

In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total value of $271,831.50. Following the sale, the director now owns 6,929 shares in the company, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey C. Kunins sold 21,834 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $593.88, for a total transaction of $12,966,775.92. Following the transaction, the insider now owns 154,394 shares of the company’s stock, valued at $91,691,508.72. This trade represents a 12.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,545 shares of company stock worth $30,721,337 over the last quarter. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Asset Dedication LLC increased its position in Axon Enterprise by 11.3% during the fourth quarter. Asset Dedication LLC now owns 178 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 18 shares during the last quarter. Bleakley Financial Group LLC boosted its stake in shares of Axon Enterprise by 1.3% during the fourth quarter. Bleakley Financial Group LLC now owns 1,527 shares of the biotechnology company’s stock valued at $908,000 after purchasing an additional 20 shares during the period. Insigneo Advisory Services LLC increased its stake in Axon Enterprise by 1.4% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock worth $627,000 after buying an additional 22 shares during the period. Menard Financial Group LLC grew its stake in Axon Enterprise by 0.8% in the 3rd quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock worth $1,204,000 after acquiring an additional 24 shares in the last quarter. Finally, PFG Investments LLC raised its stake in shares of Axon Enterprise by 0.6% during the third quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock valued at $1,547,000 after acquiring an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.